Critics say stem cell panel skirting the law; Board didn't give proper notice of meeting, they say
By San Francisco Chronicle,
San Francisco Chronicle
| 12. 16. 2004
Even before its first meeting, the board being created to direct California's $3 billion stem cell program is stirring up controversy about whether it is complying with the state's open-government rules.
Terry Francke, general counsel of a Sacramento public interest group called Californians Aware, urged state Attorney General Bill Lockyer to delay the inaugural meeting of the stem cell board, scheduled for Friday in San Francisco.
In a letter to Lockyer, Francke gave his "strong endorsement" of a protest filed by Charles Halpern, an independent public interest lawyer in Berkeley who is alleging the official agenda and public notice for the Friday meeting fail to comply with the state Bagley-Keene Act, which mandates open meetings of public agencies.
Halpern previously had tried to win a seat on the board, known as the Independent Citizens Oversight Committee. Although that didn't happen, Halpern said he still intends to make his views known as the stem-cell enterprise gets under way.
Halpern asserted that planners of the Friday meeting did not provide enough advance notice, gave only cursory descriptions of agenda items, provided no...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
